PL375893A1 - Treatment of chronic heart failure - Google Patents

Treatment of chronic heart failure

Info

Publication number
PL375893A1
PL375893A1 PL03375893A PL37589303A PL375893A1 PL 375893 A1 PL375893 A1 PL 375893A1 PL 03375893 A PL03375893 A PL 03375893A PL 37589303 A PL37589303 A PL 37589303A PL 375893 A1 PL375893 A1 PL 375893A1
Authority
PL
Poland
Prior art keywords
treatment
heart failure
chronic heart
chronic
failure
Prior art date
Application number
PL03375893A
Other languages
English (en)
Polish (pl)
Inventor
Lin Zhao
Original Assignee
Tap Pharmaceutical Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Products Inc. filed Critical Tap Pharmaceutical Products Inc.
Publication of PL375893A1 publication Critical patent/PL375893A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL03375893A 2002-12-20 2003-12-11 Treatment of chronic heart failure PL375893A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/325,420 US20040122067A1 (en) 2002-12-20 2002-12-20 Treatment of chronic heart failure

Publications (1)

Publication Number Publication Date
PL375893A1 true PL375893A1 (en) 2005-12-12

Family

ID=32593758

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375893A PL375893A1 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Country Status (7)

Country Link
US (1) US20040122067A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581308A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006514051A (cg-RX-API-DMAC7.html)
CA (1) CA2506719A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006628A (cg-RX-API-DMAC7.html)
PL (1) PL375893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004060489A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US20170217948A1 (en) 2014-07-30 2017-08-03 Teijin Pharma Limited Xanthine oxidase inhibitor
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) * 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
AU1520699A (en) * 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
CZ297264B6 (cs) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
DE69942009D1 (de) * 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
EP1212064A2 (en) * 1999-03-09 2002-06-12 Max-Delbrück-Centrum Für Molekulare Medizin Use of inhibitors of endotoxin for the treatment of heart failure and of cachexia

Also Published As

Publication number Publication date
MXPA05006628A (es) 2005-09-30
WO2004060489A3 (en) 2004-11-25
JP2006514051A (ja) 2006-04-27
EP1581308A2 (en) 2005-10-05
CA2506719A1 (en) 2004-07-22
WO2004060489A2 (en) 2004-07-22
US20040122067A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL218909A0 (en) Treatment of diabetes
EP1804914A4 (en) BAROREFLEX ACTIVATION AND HEART RESYNCHRONIZATION FOR THE TREATMENT OF HEART FAILURE
GB0201674D0 (en) Medical treatment
GB0218879D0 (en) Medical treatment
GB0223367D0 (en) Therapeutic treatment
IL164078A0 (en) Treatment of lung disorder
GB0213869D0 (en) The treatment of pain
GB0223854D0 (en) Therapeutic treatment
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
PT1534296E (pt) UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA
GB0210464D0 (en) Therapeutic treatment
GB0221712D0 (en) Methods of treatment
EP1474151A4 (en) METHODS OF TREATING CHRONIC IMMUNE DISEASE
GB2409655B (en) Treatment of fluids
PL372900A1 (en) Treatment of metabolic syndrome
AUPS020602A0 (en) Treatment for heart failure
GB0211515D0 (en) Blood treatment
AU2003900407A0 (en) Treatment for heart failure
SI1553950T1 (sl) Terapevtsko zdravljenje
SI1408977T1 (sl) Kombinacijska terapija za zdravljenje srcne insuficence
GB0223405D0 (en) Medical treatment
GB0220849D0 (en) Medical treatment

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)